David Venables, PhD

"I am impressed by the science being developed and seeing how it can be used to solve problems in the development of novel therapeutics, particularly in cell and gene therapy."

David Venables, PhD

President, AskBio Europe

Prior to joining AskBio, David Venables has held a number of executive-level technical and business roles in the biotechnology industry over the last 25 years. Most recently, he was CEO at Synpromics, a company acquired by AskBio in April 2019. Before that, he served as founding CEO of Anatara Therapeutics (Australia); CEO of Ark Therapeutics with responsibility for leading the company through a transition to a viral contract development and manufacturing service model and ultimately a sale of the business assets; an advisor to Syncona Partners and VP – CMC for NightstaRx, an ophthalmology focused gene therapy company formed by Syncona.

Dr. Venables also worked at Intercell, where he was responsible for building its manufacturing capabilities in Europe and the U.S. As site head for vaccine manufacturing operations in the UK, he was responsible for the European and U.S. licensure, pre-approval inspection and commercial supply of Ixiaro®, a Japanese encephalitis vaccine, and followed as Chief Operating Officer of Intercell USA.